Viking Therapeutics (LTS:0VQA) Dividends per Share : $0.00 (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Viking Therapeutics Dividends per Share?

Viking Therapeutics's dividends per share for the three months ended in Mar. 2025 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2025 was 0.00. As of today, Viking Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Viking Therapeutics Dividends per Share Historical Data

The historical data trend for Viking Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Dividends per Share Chart

Viking Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Viking Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Viking Therapeutics's Dividends per Share

For the Biotechnology subindustry, Viking Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Viking Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Viking Therapeutics (LTS:0VQA) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Viking Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2025 )	/	EPS without NRI (Q: Mar. 2025 )
	=	0	/	-0.41
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Viking Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (LTS:0VQA) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

VKTX:USA 1VT:Germany 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Headlines

No Headlines